8-K
filed February 12, 2026, 6:59 PM ET
ticker LNAI
CIK 0001527728
regulatory
confidence high
sentiment negative
materiality 0.85
Lunai Bioworks receives Nasdaq delisting notice; appeals hearing requested
Lunai Bioworks Inc.
- Notice received Feb 6, 2026: bid price closed below $1.00 for 30 consecutive business days through Feb 5, 2026.
- Ineligible for 180-day compliance period due to 1-for-10 reverse stock split on Sep 30, 2025 (Nasdaq Rule 5810(c)(3)(A)(iv)).
- Suspension and Form 25 filing scheduled for Feb 18, 2026 unless hearing request stays action.
- Company timely requested hearing before Nasdaq Hearings Panel by Feb 13, 2026; outcome uncertain.
- Delisting would deregister securities under Section 12(b) of Exchange Act.
Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0001731122-26-000221
- form_type
- 8-K
- ticker
- LNAI
- cik
- 0001527728
- company_name
- Lunai Bioworks Inc.
- filed_at
- 2026-02-12T23:59:59+00:00
- discovered_at
- 2026-05-14T18:02:35.334823+00:00
- generated_at
- 2026-05-16T03:00:23.377919+00:00
- sec_items
- ["3.01", "7.01"]
- event_type
- regulatory
- sentiment
- negative
- materiality_score
- 0.85
- calibrated_materiality_score
- 0.85
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0001731122-26-000221
- json_url
- https://secwatch.observer/filing/0001731122-26-000221.json
- markdown_url
- https://secwatch.observer/filing/0001731122-26-000221.md
- text_url
- https://secwatch.observer/filing/0001731122-26-000221.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/1527728/000173112226000221/0001731122-26-000221-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/1527728/000173112226000221/e7323_8-k.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
ATNM
Actinium receives NYSE American non-compliance notice for low stockholders' equity; must submit plan by June 26
Actinium Pharmaceuticals, Inc.
May 29, 2026, 5:10 PM ET
regulatory
Items 3.01, 7.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01, 7.01
same event type: regulatory
similar materiality
This filing
February 6, 2026, Lunai Bioworks, Inc. (the “Company”)
received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”)
notifying the Company that Nasdaq staff has determined to delist the Company’s securities from The Nasdaq Capital Market. The Notice states that the Company is not in compliance with Nasdaq Listing
Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share, as the bid price of the Company’s securities closed below
$1.00 per share for 30 consecutive business days from December 23, 2025 through February 5
Comparable filing
May 27, 2026, Actinium Pharmaceuticals, Inc.
(the “Company”) received a notice (the “Notice”) from NYSE American LLC (“NYSE American”) indicating
that the Company is not in compliance with the continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company
Guide (the “Company Guide”), which requires a listed company to maintain stockholders’ equity of $4.0 million or more
if it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. As of March 31,
2026, the Company reported stockholders’ equity of approximately
Filing page
SEC filing
VSTD
Vestand receives Nasdaq delisting notice for late quarterly and annual filings
Vestand Inc.
May 26, 2026, 5:18 PM ET
regulatory
Items 3.01, 7.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01, 7.01
same event type: regulatory
similar materiality
This filing
February 6, 2026, Lunai Bioworks, Inc. (the “Company”)
received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”)
notifying the Company that Nasdaq staff has determined to delist the Company’s securities from The Nasdaq Capital Market. The Notice states that the Company is not in compliance with Nasdaq Listing
Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share, as the bid price of the Company’s securities closed below
$1.00 per share for 30 consecutive business days from December 23, 2025 through February 5
Comparable filing
May 19, 2026, the Company received a Staff Delisting Determination letter (the “Staff Determination”) from Nasdaq notifying
it that Nasdaq has initiated a process which could result in the delisting of the Company’s secu
Filing page
SEC filing
NVVE
Nuvve receives Nasdaq delisting notice for late Q1 10-Q filing; already under $1.00 bid price review
Nuvve Holding Corp.
May 22, 2026, 6:35 PM ET
regulatory
Items 3.01, 7.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01, 7.01
same event type: regulatory
similar materiality
This filing
February 6, 2026, Lunai Bioworks, Inc. (the “Company”)
received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”)
notifying the Company that Nasdaq staff has determined to delist the Company’s securities from The Nasdaq Capital Market. The Notice states that the Company is not in compliance with Nasdaq Listing
Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share, as the bid price of the Company’s securities closed below
$1.00 per share for 30 consecutive business days from December 23, 2025 through February 5
Comparable filing
May 22, 2026, Nuvve Holding Corp. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, since the Company
Filing page
SEC filing
AGAE
AGAE receives Nasdaq delisting notice over bid price <$1.00 and late 10-K; will appeal
Allied Gaming & Entertainment Inc.
May 11, 2026, 5:09 PM ET
regulatory
Items 3.01, 5.03, 7.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01, 7.01
same event type: regulatory
similar materiality
This filing
February 6, 2026, Lunai Bioworks, Inc. (the “Company”)
received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”)
notifying the Company that Nasdaq staff has determined to delist the Company’s securities from The Nasdaq Capital Market. The Notice states that the Company is not in compliance with Nasdaq Listing
Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share, as the bid price of the Company’s securities closed below
$1.00 per share for 30 consecutive business days from December 23, 2025 through February 5
Comparable filing
termination
before an independent Hearings Panel (the “Panel”) by May 13, 2026. On November 4, 2025, Staff notified the Company
that the bid price of the Common Stock had closed at less than $1.00 per share over 30 consecutive business days, and, as a result, did
not comply with Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Rule”). The Staff Determination was issued pursuant
to Nasdaq Listing Rule 5810(c)(3)(A) on the grounds that the Company has not regained compliance with the Minimum Bid Price Rule during
a 180-day compliance period and is not eligible for a second 180-day complian
Filing page
SEC filing
SBEV
Splash Beverage receives NYSE delisting notice; shareholders' equity negative $15.3M
SPLASH BEVERAGE GROUP, INC.
May 5, 2026, 7:59 PM ET
regulatory
Items 1.01, 1.02, 3.01, 3.02, 5.03, 7.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01, 7.01
same event type: regulatory
similar materiality
This filing
February 6, 2026, Lunai Bioworks, Inc. (the “Company”)
received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”)
notifying the Company that Nasdaq staff has determined to delist the Company’s securities from The Nasdaq Capital Market. The Notice states that the Company is not in compliance with Nasdaq Listing
Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share, as the bid price of the Company’s securities closed below
$1.00 per share for 30 consecutive business days from December 23, 2025 through February 5
Comparable filing
April 29, 2026, the Company received notice from NYSE Regulation (the “NYSE”)
that the Company is not in compliance with the shareholders’ equity requirement of $6 million as of December 31, 2025 as outlined
in Section 1
Filing page
SEC filing
VSTD
Vestand receives Nasdaq delisting notice for late 10-K filing; may submit compliance plan by May 18, 2026
Vestand Inc.
April 29, 2026, 7:59 PM ET
regulatory
Items 3.01, 7.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01, 7.01
same event type: regulatory
similar materiality
This filing
February 6, 2026, Lunai Bioworks, Inc. (the “Company”)
received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”)
notifying the Company that Nasdaq staff has determined to delist the Company’s securities from The Nasdaq Capital Market. The Notice states that the Company is not in compliance with Nasdaq Listing
Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share, as the bid price of the Company’s securities closed below
$1.00 per share for 30 consecutive business days from December 23, 2025 through February 5
Comparable filing
April 23, 2026, Vestand Inc. (the “Company”) received a staff deficiency notice (the “Notice”) from The Nasdaq
Stock Market (“Nasdaq”) indicating that, because Nasdaq has not yet received the Company’s Form 10-K for the
Filing page
SEC filing
JAGX
Jaguar Health granted Nasdaq extension to May 15, 2026; announces 1-for-35 reverse stock split
Jaguar Health, Inc.
April 27, 2026, 7:59 PM ET
regulatory
Items 3.01, 3.03, 5.03, 7.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01, 7.01
same event type: regulatory
similar materiality
This filing
February 6, 2026, Lunai Bioworks, Inc. (the “Company”)
received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”)
notifying the Company that Nasdaq staff has determined to delist the Company’s securities from The Nasdaq Capital Market. The Notice states that the Company is not in compliance with Nasdaq Listing
Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share, as the bid price of the Company’s securities closed below
$1.00 per share for 30 consecutive business days from December 23, 2025 through February 5
Comparable filing
April 24, 2026, Jaguar Health, Inc. (the “Company”) received a decision letter from the Nasdaq Hearings Panel (“Panel”) granting the Company’s request to continue its listing on The Nasdaq Stock Market LLC (“Nasdaq”), su
Filing page
SEC filing
ISPC
iSpecimen flagged for Nasdaq equity shortfall; equity $814K vs $2.5M minimum
iSpecimen Inc.
June 1, 2026, 5:00 PM ET
regulatory
Items 3.01
same fact type: exchange_compliance_notice
same SEC item: 3.01
same event type: regulatory
similar materiality
This filing
February 6, 2026, Lunai Bioworks, Inc. (the “Company”)
received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”)
notifying the Company that Nasdaq staff has determined to delist the Company’s securities from The Nasdaq Capital Market. The Notice states that the Company is not in compliance with Nasdaq Listing
Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share, as the bid price of the Company’s securities closed below
$1.00 per share for 30 consecutive business days from December 23, 2025 through February 5
Comparable filing
May 29, 2026, iSpecimen Inc. (the “Company”)
received a letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”)
notifying the Company that it no longer complies with Nasdaq Listing Rule 5550(b)(1) (the “Rule”), which requires a minimum
of $2,500,000 in stockholders’ equity for continued listing on the Nasdaq Capital Market (the “Capital Market”). As reported in the Company’s Quarterly Report
on Form 10-Q for the period ended March 31, 2026, the Company had stockholders’ equity of $814,038. Nasdaq noted that, as of May
29, 2026, the Company doe
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.